Dadao Longda

Beijing Dadao Longda Biotechnology is a biopharmaceutical company dedicated to the development of innovative D-peptide drugs. The company utilizes a proprietary platform to engineer peptides composed of D-amino acids, which are designed to be more resistant to enzymatic degradation and less immunogenic than standard L-peptides. Their lead research programs focus on neurodegenerative conditions, specifically Alzheimer's disease, alongside efforts in oncology and metabolic health. Dadao Longda aims to bridge the gap between basic research and clinical application by advancing a pipeline of stable, high-affinity peptide therapeutics.